BGF is a prominent growth capital investor operating across the United Kingdom and Ireland, providing patient funding to small and mid-sized enterprises.
The Series B round was led by bp ventures with participation from a global investor syndicate.
"We are very excited about the amazing endorsement we have received from new and existing investors. This round of investment marks a key chapter in Oxbotica’s continued growth and pushes us forward in commercialising our autonomous software today, through key strategic go-to-market partnerships. The high-quality and global footprint of our investors cements our position as a leader in autonomy. We will use funds raised to accelerate the global deployment of our transformative technology."
The seed round was co-led by BGF and Longwall Venture Partners with participation from seed backers including BioCity, Alderley Park Ventures, and Puffin Point.
"This marks a huge step forward for Kinomica and for KScan™, as we look to the future of cancer treatment. Our pioneering technology offers much-needed support for the development of new precision medicines and represents a new approach to drug trials and treatments that will have a huge impact on patients’ lives."
The Bristol-based HR and payroll software provider has raised £2m from BGF to support its organic and acquisitive growth strategy.
"We are extremely excited to be partnering with BGF with this investment. It not only means our plans are funded, but also gives us validation that an investor with a reputation such as BGF’s believes in what we have achieved up to this point."
The financing round will secure the roadmap to the company's first orbital launch from Sutherland.
"Orbex is an impressive UK company which is developing a strongly differentiated and innovative launch solution for the rapidly-growing small satellite market. In Europe, they are a recognized leader with an experienced team, substantial institutional support, a growing customer list and patented technology. The private space sector remains a key future industry for both Scottish and UK governments and we’re very excited to be backing one of the most compelling examples of this evolving sector,"
BGF led the round with participation from 24Haymarket to support US expansion and site growth.
"Our technology platform harnesses iPSC technology to develop models that are transformational for drug discovery. We have gained significant commercial momentum in recent years, and this investment will be a significant driver of continued growth for DefiniGEN. We’re thrilled to be working with BGF, who understand the complex issues that we are addressing and are committed to helping us accelerate the next phase of growth."
